Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 548.74 per share at the end of the most recent trading day (a -0.07% change compared to the prior day closing price) with a volume of 70.24K shares and market capitalization of 16.30B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class A stock is -28.36%, while year-to-date (YTD) performance is -27.37%. BIO stock has a five-year performance of 154.18%. Its 52-week range is between 462.61 and 832.7, which gives BIO stock a 52-week price range ratio of 23.27%

Bio-Rad Laboratories Inc. Class A currently has a PE ratio of -8.30, a price-to-book (PB) ratio of 1.83, a price-to-sale (PS) ratio of 4.71, a price to cashflow ratio of 34.00, a PEG ratio of 2.32, a ROA of -13.97%, a ROC of -17.71% and a ROE of -18.93%. The company’s profit margin is -67.66%, its EBITDA margin is -85.80%, and its revenue ttm is $2.87 Billion , which makes it $116.55 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.46 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is -.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1), with a target price of $776.67, which is +41.54% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 9.34, ATR14 : 18.63, CCI20 : 57.32, Chaikin Money Flow : 0.07, MACD : 9.87, Money Flow Index : 67.73, ROC : 0.38, RSI : 50.99, STOCH (14,3) : 57.53, STOCH RSI : 0.99, UO : 47.66, Williams %R : -42.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Ajit Ramalingam (Sold 518 shares of value $278 166 ), Andrew J. Last (Option Excercise at a value of $598 480), Andrew J. Last (Sold 2 000 shares of value $1 626 203 ), Annette Tumolo (Option Excercise at a value of $1 799 043), Annette Tumolo (Sold 6 946 shares of value $5 233 746 ), Dara Wright (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $283 122), Ilan Daskal (Sold 810 shares of value $668 537 ), Michael Crowley (Option Excercise at a value of $0), Norman Schwartz (Option Excercise at a value of $3 702 220), Timothy S. Ernst (Option Excercise at a value of $0)